Researchers assessed long-term effectiveness and tolerability of brivaracetam in patients with focal epilepsy. According to this multicenter retrospective study, brivaracetam was effective and well-tolerated in a large population of patients with predominantly drug-resistant epilepsy. There were no unexpected adverse events (AEs) over 1 year. The most frequently reported AEs were somnolence, irritability and dizziness.
March 25, 2020
Study Finds Pregabalin (Lyrica®) Adjunctive Therapy Significantly Reduces Seizure Rate in Children One Month to Over Four Years with Focal Onset Seizures
Pregabalin 14 mg/kg/d (but not 7 mg/kg/d) significantly reduced seizure rate in children with focal-onset seizures, when assessed using V?EEG, compared with placebo.
March 24, 2020
Study Finds Levetiracetam Not Significantly Better Than Phenytoin in Ending Seizures in Patients with Established Status Epilepticus
Moderate-quality evidence suggested that levetiracetam was not significantly superior to phenytoin in seizure cessation in patients with established status epilepticus.